Replies to post #164612 on Elite Pharmaceuticals Inc (ELTP)

[mrwrn2010]

Yep that's what I've been saying ever since we first got the HAL results. It's huge. Abuser can't tell between a sugar pill and our opioid when crushed. Huge!!!

[WeeZuhl]

There may be more there, JJ.

Patients who snorted the ELI-200 thought they were snorting the placebo. Nice.

It seems to be something even a little better than “same as placebo.” I’m particularly referring to the initial downslope on ELI-200. This is more than just euphoria-blocking as we would expect from an antagonist ADF. This graph suggests that ELI-200 may have AVERSIVE properties, which I did not expect.




Now compare the ELI-200 line above with the niacin lines below. Niacin is an aversive ADF agent that was used in some oxycodone formulations by Acura because it causes nasal irritation when snorted. The predecessor to Oxaydo being marketed by Egalet contained niacin. Niacin was ordered out of all formulations by FDA- partially because it is of dubious ethical standards to subject every appropriate user with a dose of unnecessary niacin- but mostly because it is a crappy ADF and only delays euphoria, as seen below. Black circle and square are oxy alone and white circle and square are oxy with niacin. Just like ELI-200, the niacin formulations are initially *disliked* beyond placebo. But unlike ELI-200, the niacin subjects are feeling pretty groovy within 1 hour and are completely stoned within 2 hours.






The ELI-200 flat-line drug-liking curve is entirely expected and proves ELI-200’s euphoria-blocking antagonist effects. But the suggestion of this graph that ELI-200 may also be an AVERSIVE agent is new information and very intriguing. It would certainly be a marketable trait. I am not aware of any other ADFs that currently claim aversive properties.

[John_Langston]

But the patients that separated the two beads got so high.